about
Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the DrawbacksGenetic characterization of caffeine degradation by bacteria and its potential applicationsMetabolic syndrome: an important risk factor for Parkinson's diseaseStructure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and CaffeineEmbryonic caffeine exposure acts via A1 adenosine receptors to alter adult cardiac function and DNA methylation in miceWinning a Won Game: Caffeine Panacea for Obesity SyndemicAdenosine Receptors: The Contributions by John W. Daly.Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.Regulation of multiple tip formation by caffeine in cellular slime moldsAcute atrial arrhythmogenesis in murine hearts following enhanced extracellular Ca(2+) entry depends on intracellular Ca(2+) stores.Novel N-methylated 8-oxoisoguanines from Pacific sponges with diverse neuroactivitiesPharmacological changes in cellular Ca2+ homeostasis parallel initiation of atrial arrhythmogenesis in murine Langendorff-perfused hearts.Uric acid as one of the important factors in multifactorial disorders--facts and controversies.The implications of relationships between human diseases and metabolic subpathways.Xanthines as adenosine receptor antagonists.Coffee intake and development of pain during computer workCaffeine's Vascular Mechanisms of ActionCaffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.Sleep variability, health-related practices, and inflammatory markers in a community dwelling sample of older adults.Caffeine consumption does not have an effect on digital microvascular perfusion assessed by laser Doppler imaging on healthy volunteers: a pilot study.I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis.Synthesis and anticancer activity of silver(I)-N-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine.No Enhancement of 24-Hour Visuomotor Skill Retention by Post-Practice Caffeine AdministrationCaffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival.Methylxanthines and the kidney.Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistanceArachidonic acid enhances caffeine-induced cell death via caspase-independent cell death.Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.Direct conversion of theophylline to 3-methylxanthine by metabolically engineered E. coli.Stress, caffeine and ethanol trigger transient neurological dysfunction through shared mechanisms in a mouse calcium channelopathyMolecular and pharmacodynamic interactions between caffeine and dopaminergic system.Caffeine fostering of mycoparasitic fungi against phytopathogens.Caffeine inhibits acetylcholinesterase, but not butyrylcholinesteraseAbnormal Ca(2+) homeostasis, atrial arrhythmogenesis, and sinus node dysfunction in murine hearts modeling RyR2 modificationEmbryonic caffeine exposure induces adverse effects in adulthoodUncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling.Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants.Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Engineering a microbial platform for de novo biosynthesis of diverse methylxanthines.
P2860
Q26740559-1EA8E05D-C759-46BD-9CCE-8042D36BFB9CQ26852833-20328F29-7EDE-4128-90CC-688C5BD5D2C8Q27023711-B5C91CFA-65D4-4CEE-A31B-4648FCF776DDQ27672832-8C722A9B-F17C-40FC-B306-13198C326437Q28539215-9A25076E-1756-40CF-839F-E2608926BB2AQ29540785-F17AFBB1-F1CF-4268-AAAF-A9F5A091231BQ30384658-9B0AFE0F-775C-4BB4-9E98-6343B4A86843Q30396823-61F340E1-EB0D-4823-B228-809D63358805Q30527866-DF1D9B85-B592-48B0-BF31-9A40BF863E85Q33514742-EC73BE31-898E-4BF2-BBB4-A497057D8ABAQ33648369-03085D3E-B005-41D8-9102-BA418323FB8CQ33739827-E3031E06-4D76-4818-814A-53171B0929DFQ33773142-0EF30E09-A216-4503-9A77-12055D6877D1Q33939198-4C7AF1A8-E90A-41E4-AC00-ED7E2F1634DBQ34139398-33A6B924-F527-45BA-8684-996A720E5A38Q34402003-8478218E-F58A-4336-B278-41B14C68947BQ34415153-ED20BAAF-FD99-42AB-A368-459198C15B60Q34905120-A495221F-63CF-48F6-A938-0844E4123DA2Q35020413-DA0ED74D-6D14-417F-B388-72351075849CQ35249148-0711E1ED-31C5-4D3F-B567-F718566C9C9EQ35560040-0121173F-B6C8-47F8-859C-29808633D124Q35587732-B7CE31DE-7AE1-42CB-BC57-94D66351A4A4Q35656467-16DC3850-BA58-4308-8926-68613C3633F2Q35740983-CB870B26-AE35-43F4-978C-C0A732B2D6E6Q35745752-FBFA1A2C-9533-4290-8185-6059B44F4337Q35776784-C187BCDA-8A71-4843-B8E5-B884AA5755B1Q36164982-D6B1E2CB-DA19-466A-93D3-0BCC7EC14729Q36296595-08606A40-06DB-45C8-9135-E06E77424659Q36393688-CE404F4D-E005-4D45-86A4-8C0D72E49864Q36501625-BC771BEA-F86B-4040-BB0F-1B1463C47B50Q36744872-D6428673-ED16-47D1-A61E-A58606183FEDQ36913243-4E5D857B-BE0A-4073-B1AB-C9D2750155C8Q36913687-912028EC-6715-4B3F-81D9-92DC53A99321Q36952000-A8F5D07D-F78A-4008-954C-34A645D747EFQ37139819-F7006F7A-6065-4137-976B-4AC66B6F07ECQ37200611-E44387D0-B991-42FF-9564-703AB518F1CEQ37700718-D7953EAB-A050-4687-94B5-2526188238E3Q38199970-F4D54E05-676B-4D15-8FBE-41CCABC4B87EQ38584194-746D5F5F-97F5-4837-AABF-EFEE036C50ABQ39494705-85F79887-D8D4-412A-9808-1A07978AF711
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Caffeine analogs: biomedical impact.
@ast
Caffeine analogs: biomedical impact.
@en
Caffeine analogs: biomedical impact.
@nl
type
label
Caffeine analogs: biomedical impact.
@ast
Caffeine analogs: biomedical impact.
@en
Caffeine analogs: biomedical impact.
@nl
prefLabel
Caffeine analogs: biomedical impact.
@ast
Caffeine analogs: biomedical impact.
@en
Caffeine analogs: biomedical impact.
@nl
P1476
Caffeine analogs: biomedical impact.
@en
P2093
P2888
P304
P356
10.1007/S00018-007-7051-9
P577
2007-08-01T00:00:00Z